AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04595084 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Based Cognitive Therapy for Resilience During COVID-19 plus CHAMindWell
Description: MBCT-R is designed to foster resilience and prevent new-onset anxiety and depression disorders or exacerbation of existing conditions. MBCT-R follows the MBCT structure of eight classes and one half-day retreat, with home practice and specific daily meditation, but is live-online and focuses on specific stressors (COVID-19, its economic and social consequences). Classes of 40-50 participants are led by 2 co-leaders. Participants have CHA MindWell Monitoring and telephone support during weeks 1-8 and then every 4 weeks afterwards for 24 weeks. Participants with severe symptoms or worsening moderate symptoms will be asked if they would like a mental wellness assessment with a clinician. If monitoring with CAT-MH interviews suggests symptomatic worsening, then a CHA MindWell technician will contact the participant and check-in and offer support, including setting up a televisit with a member of a clinical member of the outpatient mental health team if needed.
Study NCT04595084 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Internet Cognitive Behavioral Therapy plus CHAMindWell
Description: MoodGYM is based on CBT and interpersonal therapy targeting depression, anxiety, stress, and general psychological distress. MoodGYM has 6 sessions with five curriculum modules and a review session that can be completed within an 8-week period. iCBT participants will also be enrolled in CHA MindWell Monitoring and Support (CHA-MW). Participants across arms will have CHA MindWell Monitoring and Technician telephone support during weeks 1-8 and then every 4 weeks afterwards for 24 weeks. Participants with severe symptoms or worsening moderate symptoms will be asked if they would like a mental wellness assessment with a clinician. If there are difficulties with accessing iCBT technology or if monitoring with CAT-MH or CAT-DI/ANX-CAT interviews suggests symptomatic worsening, then a CHA MindWell technician will contact the participant and check-in and offer support, including setting up a televisit with a member of a clinical member of the outpatient mental health team if needed.
Study NCT04595084 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CHAMindWell
Description: Participants across arms will have CHA MindWell Monitoring and Technician support during weeks 1-8 and then every 4 weeks afterwards for 24 weeks. Participants across arms will have CHA MindWell Monitoring and Technician telephone support during weeks 1-8 and then every 4 weeks afterwards for 24 weeks. Participants with severe symptoms or worsening moderate symptoms will be asked if they would like a mental wellness assessment with a clinician. If monitoring with CAT-MH or CAT-DI/ANX-CAT interviews suggests symptomatic worsening, then a CHA MindWell technician will contact the participant and check-in and offer support, including setting up a televisit with a member of a clinical member of the outpatient mental health team if needed.
Study NCT04595084 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CHAMindWell
Description: Participants across arms will have CHA MindWell Monitoring and Technician support during weeks 1-8 and then every 4 weeks afterwards for 24 weeks. Participants across arms will have CHA MindWell Monitoring and Technician telephone support during weeks 1-8 and then every 4 weeks afterwards for 24 weeks. Participants with severe symptoms or worsening moderate symptoms will be asked if they would like a mental wellness assessment with a clinician. If monitoring with CAT-MH or CAT-DI/ANX-CAT interviews suggests symptomatic worsening, then a CHA MindWell technician will contact the participant and check-in and offer support, including setting up a televisit with a member of a clinical member of the outpatient mental health team if needed.
Study NCT04998383 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HVNI
Description: High velocity nasal insufflation (Fisher \&Paykel, Auckland, New Zealan High-velocity nasal insufflation (Precision Flow;Vapotherm, Inc, Exeter, NH) (Figure 2) using a smallborenasal cannula was initiated with a flow rate set to 35 L/min, with a starting temperature between 35C and 37C and FiO2 at 1.0. Adjustments in flow (up to 40 L/min) and temperature (typically between 35C and 37C) were made to alleviate respiratory distress and optimize comfort.
Study NCT04891627 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Gingival crevicular fluid
Description: GCF samples were collected in the morning hours 24-48 hours after clinical periodontal measurement.
Study NCT04671355 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Beclometasone Dipropionate / Formoterol Fumarate / Glycopyrronium 100/6/10 mcg
Description: Pressurized metered dose inhaler
Study NCT04671355 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone Furoate / Vilanterol Trifenatate 100/25 mcg
Description: Dry powder inhaler
Study NCT05034536 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Intravenous infusion
Study NCT05034536 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infliximab
Description: Intravenous infusion
Study NCT05034536 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Intravenous infusion
Study NCT05034536 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Relatlimab
Description: Intravenous infusion
Study NCT05034536 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Intravenous infusion
Study NCT05184777 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Determination of progesterone and oestradiol
Description: Blood and saliva samples will be taken for determination of progesterone and oestradiol hormones.
Study NCT06486675 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: education
Description: breastfeeding consultant training
Study NCT05876169 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Orthognathic surgery
Description: Surgical corrections of the maxilla and/or the mandible. Integrated jaw-neck movement patterns, muscle activity, bite force and occlusal contact area will be registered and mapped with quantitative objective functional variables. The state-of-the-art core equipment to evaluate jaw-neck motor function in detail is located in the Movement Lab (Department of Odontology, Umeå University).
Study NCT05635500 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Different Approach to endotracheal intubation.
Description: Different insertion way.
Study NCT03947775 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 9-valent HPV vaccination
Description: Gardasil-9 is a novel, 9-valent HPV recombinant vaccine, which expands the coverage of oncogenic HPV types, with the addition of HPV types 31, 33, 45, 52, and 58 to the existing quadrivalent vaccine types. The addition of these five oncogenic types is estimated to improve cancer coverage to 90% (versus 70% for the quadrivalent vaccine) \[38\]. With its expanded coverage of oncogenic HPV types, its proven efficacy in primary prevention and its potential role in mitigating HGAIN recurrences.
Study NCT03947775 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 9-valent HPV vaccination
Description: Gardasil-9 is a novel, 9-valent HPV recombinant vaccine, which expands the coverage of oncogenic HPV types, with the addition of HPV types 31, 33, 45, 52, and 58 to the existing quadrivalent vaccine types. The addition of these five oncogenic types is estimated to improve cancer coverage to 90% (versus 70% for the quadrivalent vaccine) \[38\]. With its expanded coverage of oncogenic HPV types, its proven efficacy in primary prevention and its potential role in mitigating HGAIN recurrences.
Study NCT04745507 — intervention group
Intervention type: OTHER
Intervention: Inpatient Equivalent Home Treatment
Description: At-home psychiatric treatment by means of a multiprofessional clinic team (an equivalent to stationary psychiatric care).
Study NCT04611776 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab will be administered intravenously during the induction phase and the maintenance phase.
Study NCT04611776 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered intravenously during the induction phase and the maintenance phase.
Study NCT04611776 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin will be administered intravenously during the induction phase.
Study NCT04611776 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Carboplatin
Description: Carboplatin will be administered intravenously during the induction phase.
Study NCT04611776 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin will be administered intravenously during the induction phase.
Study NCT04611776 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cisplatin
Description: Cisplatin will be administered intravenously during the induction phase.
Study NCT04611776 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Pemetrexed will be administered intravenously during the induction phase.
Study NCT04611776 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pemetrexed
Description: Pemetrexed will be administered intravenously during the induction phase.
Study NCT04611776 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine will be administered intravenously during the induction phase.
Study NCT04611776 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Gemcitabine
Description: Gemcitabine will be administered intravenously during the induction phase.
Study NCT04611776 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel will be administered intravenously during the induction phase.
Study NCT04611776 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Paclitaxel
Description: Paclitaxel will be administered intravenously during the induction phase.
Study NCT06101537 — intervention group
Intervention type: DEVICE
Intervention: Brain temperature-pressure monitoring
Description: An intracranial pressure monitoring device that continuously records brain temperature-pressure data was used during treatment.
Study NCT04884971 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intestinal microbiota transplant (IMT)
Description: Two size 00 capsules from a single lot will be taken daily. Approximately 2.0 x 10\^11 bacteria from a healthy donor are contained in each capsule.
Study NCT05241132 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab plus chemotherapy
Description: 1. Cisplatin: 100mg/m2, injected intravenously every 3 weeks, 8 cycles (period 21 days)~2. Paclitaxel (albumin-bound) : paclitaxel, 175mg/m2, given intravenously every 3 weeks for 8 cycles (period 21 days).~3. Tislelizumab: 200mg, given intravenously every 3 weeks until disease progression or unacceptable toxicity or death or subject withdrawal of informed consent.
Study NCT05573581 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botox
Description: Botulinum toxin type A will be first injected into anterior belly of digastric muscles 2-3 days prior to any surgical intervention (for the BTX to be clinically effective)(Sadick and Matarasso 2004). A total of 20 U of Botox will be injected bilaterally by using 25g needle, 1 cc insulin syringe through extraoral approach in 4 point
Study NCT05995652 — intervention group
Intervention type: PROCEDURE
Intervention: elastography
Description: elastography
Study NCT06255925 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: KF-STRIDE® Into Work!
Description: Treatment group will receive 10 web based sessions of a strength-based training tool(once or twice a week). Sessions are approximately 60 minutes long.
Study NCT04381923 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Helmet Continuous Positive Airway Pressure (CPAP)
Description: Helmet CPAP will be initiated at a pressure of 5 cmH20 and fraction of inspired oxygen (Fi02) of \< 60%. If oxygen saturation (Sp02) remains \< 92%, pressure will be increased to 10 cmH20. FiO2 will then be tapered to target a SpO2 ≥ 92%. Breaks with intervening HFNO use will be provided as needed for meals and during hours of sleep.
Study NCT04381923 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: High Flow Nasal Oxygen (HFNO)
Description: HFNO will be initiated at a flow rate of 40 LPM and a fraction of inspired oxygen (Fi02) of \< 60%. If oxygen saturation (SpO2) remains \< 92%, the flow rate will be increased to 60 LPM. FiO2 will then be adjusted to target a SpO2 ≥ 92%. Patients with discomfort due to HFNO may have their flow rate decreased until the discomfort resolves.
Study NCT04582305 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bleomycin
Description: Intralesional bleomycin treatment administered with an electronic pneumatic jet injector
Study NCT04582305 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Intralesional placebo treatment of normal saline administered with an electronic pneumatic jet injector
Study NCT04849377 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: RT 50 Gy
Description: Radiation Therapy (RT) 50 GY
Study NCT04849377 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: RT 54 GY
Description: Radiation Therapy (RT) 54 GY
Study NCT04849377 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: RT 60 GY
Description: Radiation Therapy (RT) 60 GY
Study NCT04849377 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Induction Therapy
Description: Induction Therapy: Cisplatin, Docetaxel, Fluorouracil
Study NCT04849377 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin AUC 9.0
Study NCT04849377 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin 200
Description: 200 mg/m2
Study NCT04849377 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin 240
Description: 240mg/m2
Study NCT06144593 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary macronutrient composition
Description: Intermittent carbohydrate restriction
Study NCT04709978 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Videofluoroscopic Swallowing Study
Description: Participants enrolled in supplemental study will swallow different barium containing liquid and food boluses types that are captured on fluoroscopic imaging in real time.
Study NCT04709978 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Nuclear medicine pulmonary aspiration study
Description: Participants enrolled in supplemental study will be administered radiotracer (Tc-99m-Sulfur Colloid) orally and static images of the chest will then be obtained at specified intervals over the next 2 hours to determine location of the radiotracer.
Study NCT04709978 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: TOR-BSST and 3 oz Water Swallow
Description: The research specialist will conduct ten 1 tsp water swallows, one cup sip of water and a 3 ounce water swallow test with the patient. After each swallow, the participant is asked to say ah so that their voice quality can be assessed.
Study NCT04709978 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Sputum Culture
Description: Patients will have sputum collected during stay (ED participants only)
Study NCT04709978 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: MeMed BV®
Description: A blood test to help determine if the infection is viral or bacterial (ED participants only)
Study NCT04709978 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Lung Ultrasound
Description: To image the lungs (ED participants only)
Study NCT04709978 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Respiratory Function Tests
Description: To measure respiratory pressures.
Study NCT04288206 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cefazolin
Description: intravenous cefazolin is being evaluated as a pre-operative prophylactic antibiotic measure with primary outcome being post operative infection rate among participants.
Study NCT04288206 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: intravenous normal saline placebo
Study NCT05596747 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3209590
Description: Administered SC.
Study NCT05596747 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Glargine
Description: Administered SC.
Study NCT06416332 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: group A: in face to face live therapeutic exercise
Description: In group A: in face to face live therapeutic exercise the program and its progressivity will be determined and performed for life according to the progress of the patient, with a frequency of sessions twice a week, session duration 45 minutes, following the recommended dosage of exercise according to clinical guidelines, while the total duration of the intervention will be eight weeks. You will be instructed to perform the program at home, 3 times a week. The standardized exercise program to be followed by this group will include :~1. Exercises to strengthen the hip and knee muscles through isometric contractions and resistance exercises using elastic bands.~2. Balance and neuromuscular coordination exercises.
Study NCT06416332 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: group B: telerehabilitation program
Description: In group B: telerehabilitation program, the therapeutic exercise program will follow the same structure, which was mentioned above. The differentiation in the intervention of this group will be that the explanation of the exercises, their presentation, monitoring and information of the participants will be done through the telerehabilitation platform and special data processing software. The intervention time remains the same, with the physical therapist during these 45 minutes of the session , to evaluate the data on the patients progress by receiving the information through the software and to inform the patient of any changes in the progressivity of the exercise program. The other parameters of the intervention remain the same, as in person exercise.
Study NCT04752033 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine
Description: Dose titration utilizing will be done using sequential up and down design using biased coin method. All participant will receive a morphine dose that is within the range of doses currently utilized clinically and no participant will receive placebo only.
Study NCT04752033 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydromorphone
Description: Dose titration utilizing will be done using sequential up and down design using biased coin method. All participant will receive a hydromorphone dose that is within the range of doses currently utilized clinically and no participant will receive placebo only.
Study NCT05353660 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study NCT04787432 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Salutogenic Frailty Prevention Program
Description: Laughter yoga: The first component of intervention is the laughter yoga that is a combination of warm up exercise, deep breathing exercises, childlike playfulness and laughter exercises. Each session of laughter yoga will be offered twice a weekly and 40 minutes each time.~Health education: The second component of intervention consisted of six health issues which are health, frailty and generalized sources of resistance for frailty, the most common medical condition and medication use, physical activity, healthy diet, falls prevention and cognitive and psychosocial well-being.~Case management: The third component of intervention is activities that determine each participant's health needs with the Omaha System and support them for the use of appropriate resources.
Study NCT05881239 — intervention group
Intervention type: DEVICE
Intervention: AROMHA Brain Health Test
Description: The AROMHA Brain Health Test is a self-administered, at-home smell test developed as a potential primary screen for identifying individuals at risk for developing Alzheimer's and as a means to follow disease progression in individuals without overt cognitive symptoms. The smell test device consists of five physical smell cards and a paired web-based app that directs participants on how to sample odors and asks them questions regarding what they have smelled. The 45-minute smell test battery includes measures of odor intensity, identification, memory, and discrimination.
Study NCT04885647 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YPEG-rhEPO
Description: YPEG-rhEPO，low dose，were subcutaneous injected once every two weeks for 13 weeks.
Study NCT04885647 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YPEG-rhEPO
Description: YPEG-rhEPO，low dose，were subcutaneous injected once every four weeks for 13 weeks.
Study NCT04885647 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YPEG-rhEPO
Description: YPEG-rhEPO, high dose，were subcutaneous injected once every two weeks for 13 weeks.
Study NCT04885647 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YPEG-rhEPO
Description: YPEG-rhEPO，high dose，were subcutaneous injected once every four weeks for 13 weeks.
Study NCT06356623 — intervention group
Intervention type: OTHER
Intervention: 1
Description: this is not an intervention study